Articles by Date (Latest First)
Filter by author: Aly W. | Lain M. | Sam S. | Mitzi
Puberty Blockers: A Review of GnRH Analogues in Transgender Youth (Mitzi, January 2022)
An Interactive Web Simulator for Estradiol Levels with Injectable Estradiol Esters (Aly W., July 2021)
An Informal Meta-Analysis of Estradiol Curves with Injectable Estradiol Preparations (Aly W., July 2021)
An Exploration of Sublingual Estradiol as an Alternative to Oral Estradiol in Transfeminine People (Sam S., June 2021)
Clinical Guidelines with Information on Transfeminine Hormone Therapy (Aly W., November 2020)
Estrogens and Their Influences on Coagulation and Risk of Blood Clots (Aly W., October 2020)
Announcing Transfeminine Science—A Site for Information on Transfeminine Hormone Therapy (Aly W., October 2020)
Prenatal Diethylstilbestrol Exposure and Likelihood of Being Transgender (Aly W., July 2020)
The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy (Aly W., July 2020)
Commentary of a New Study of Prostate Cancer Incidence in Transfeminine People Receiving Hormone Therapy (Sam S., July 2020)
Supplement: The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy (Aly W., July 2020)
Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy (Aly W., July 2020)
Injectable Estradiol Formulations Available for Transfeminine People in the United States (Aly W., June 2020)
On Changes in Bone Shape in Transfeminine Individuals Under Gender-Affirming Hormone Therapy (Lain M., May 2020)
Hormone Levels During Normal Puberty in Cisgender Girls (Aly W., April 2020)
Literature Excerpts on Spironolactone and Hormone Levels in Cisgender Women (Aly W., April 2020)
Breast Cancer Risk with Hormone Therapy in Transfeminine People (Aly W., April 2020)
Supplement: Breast Cancer Risk with Hormone Therapy in Transfeminine People (Aly W., April 2020)
Recent Developments on Cyproterone Acetate and Meningioma Risk Out of France and Implications for Transfeminine People (Aly W., April 2020)
Approximate Comparable Dosages of Estradiol by Different Routes (Aly W., April 2020)
Excerpts: Perspectives and Opinions of Clinicians and Researchers Concerning the Use of Progestogens in Transfeminine Hormone Therapy (Sam S., April 2020)
Oral versus Transdermal Estradiol in Feminising Hormone Therapy for Transgender Individuals (Sam S., April 2020)
Excerpts: Reviews, Cohort Studies and Randomised Controlled Trials Comparing the Feminising Efficacy of Estradiol Administered by Oral and Non-Oral Routes (Sam S., April 2020)
Analysis of Cardiovascular and Thromboembolic Toxicity with High Dose Parenteral Polyestradiol Phosphate in the Treatment of Prostate Cancer (Sam S., April 2020)
Dose-Ranging Data on Estradiol Patches and Testosterone Suppression in Men Based on de Ronde et al. (2009) (Aly W., April 2020)
Discussion on Women with Complete Androgen Insensitivity Syndrome, Breast Development, and Progesterone (Aly W., March 2020)
Nandrolone as an Alternative Androgen with Reduced Androgenic Side Effects for Transfeminine and Transmasculine People (Aly W., March 2020)
Excerpts: Guidance for Prolactin Monitoring and Elevated Prolactin Levels in Transfeminine People (Aly W., March 2020)
Progestogens and Breast Cancer in Transgender Women: A Review and Discussion of Risk (Sam S., February 2020)
Progesterone and its Role in Breast Development During Female Puberty (Aly W., February 2020)
The Roles of Placebo and Nocebo in Medication Effects and Why Subjective Reports Are Unreliable (Aly W., January 2020)
The Influence of Progesterone and Other Progestogens on Sexual Desire and Function (Aly W., January 2020)
A Drospirenone Progestogen-Only Birth Control Pill (Slynd) Has Been Introduced in the United States and Europe: Potential Use in Transfeminine Hormone Therapy (Aly W., December 2019)
A Review of Selective Estrogen Receptor Modulators and their Potential for Transfeminine Hormone Therapy (Lain M., October 2019)
Sources/Excerpts: A Review of Selective Estrogen Receptor Modulators and their Potential for Transfeminine Hormone Therapy (Lain M., October 2019)
Sources/Excerpts: On the Impact of Sex Hormones on Fat Metabolism with an Eye Towards Transfeminine Hormone Therapy (Lain M., September 2019)
On the Impact of Sex Hormones on Fat Metabolism with an Eye Towards Transfeminine Hormone Therapy (Lain M., September 2019)
Darolutamide (Nubeqa), a New Second-Generation Nonsteroidal Antiandrogen, Has Been Approved for Medical Use (Aly W., September 2019)
Collected Links and Excerpts on the Role of Growth Hormone (GH) and Insulin-Like Growth Factor-1 (IGF-1) in Breast Development (Aly W., August 2019)
Commentary and Fact Check of Dr. Will Powers’s Transgender Care Presentation (Aly W., August 2019)
The Relationship Between the Endocrine System and Muscle Mass (Lain M., August 2019)
Excerpts: Early Progestogen Exposure May Result in Suboptimal Breast Development (Aly W., July 2019)
Published Literature on Bicalutamide as an Antiandrogen for Transfeminine People (Aly W., July 2019)
Low Doses of Cyproterone Acetate Are Maximally Effective for Testosterone Suppression in Transfeminine People (Aly W., July 2019)
Data Show That the Number of People Hormonally Transitioning has Skyrocketed in Recent Years (Aly W., July 2019)
A Review of Studies on Estradiol Levels and Testosterone Suppression with High-Dose Transdermal Estradiol Gel and Ointment in Cisgender Men with Prostate Cancer (Aly W., June 2019)
Analysis of Sublingual Estradiol and Medroxyprogesterone Acetate (MPA) in Transfeminine People Based on Jain et al. (2019) and Deutsch et al. (2015) (Aly W., June 2019)
Injectable Aqueous Suspensions of Sex Hormones and How Depot Injectables Work (Aly W., June 2019)
An Exploration of Possibilities for Hormone Therapy in Non-Binary Transfeminine People (Aly W., June 2019)
Discussion on Cyproterone Acetate and Risk of Depression (Aly W., March 2019)
Genital Application via the Scrotum and Neolabia for Greatly Enhanced Absorption of Transdermal Estradiol in Transfeminine People (Aly W., March 2019)
Analysis of Estradiol and Testosterone Levels with Oral Estradiol in Transfeminine People Based on Leinung et al. (2018) (Aly W., March 2019)
Published Case Reports of Lactation and/or Breastfeeding in Transfeminine People (Aly W., March 2019)
Commentary and Fact Check of Dr. Jerilynn Prior’s 2019 Review on Progesterone for Transfeminine People (Aly W., March 2019)
Discussion on Bicalutamide Dosage in Transfeminine People (Aly W., March 2019)
Approval of Relugolix (Relumina), the Second Orally Active GnRH Antagonist, and Relevance for Transfeminine People (Aly W., February 2019)
Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People (Aly W., January 2019)
Administration of Oral Progesterone Capsules Rectally Instead of Orally for Greatly Improved Efficacy in Transfeminine People (Aly W., December 2018)
A Review of Studies on Spironolactone and Testosterone Levels in Cisgender Men and Transfeminine People (Aly W., December 2018)
Bicalutamide: Frequently Asked Questions and Common Misconceptions (Aly W., December 2018)
Information on Bicalutamide (Casodex) as an Antiandrogen for Transfeminine People (Aly W., September 2018)
How to Research Transfeminine Hormone Therapy in the Academic Literature and Obtain Papers (Aly W., September 2018)
Buserelin, a Gonadotropin-Releasing Hormone Agonist, is Inexpensively Available as a Nasal Spray From Online Pharmacies (Aly W., August 2018)
Oral Progesterone Achieves Very Low Levels of Progesterone and Has Only Weak Progestogenic Effects (Aly W., August 2018)
Sources/Excerpts: Oral Progesterone Achieves Very Low Levels of Progesterone and Has Only Weak Progestogenic Effects (Aly W., August 2018)
An Introduction to Hormone Therapy for Transfeminine People (Aly W., August 2018)
EC508 (Estradiol Aminosulfonylbenzoylproline), a Unique and Highly Promising Estradiol Ester and Possible Oral Estradiol Form of the Future (Aly W., August 2018)
Approval of Elagolix (Orilissa), the first Orally Active Gonadotropin-Releasing Hormone Antagonist, and Relevance for Transfeminine People (Aly W., August 2018)